4 August 2022 - Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy (semagutide) on Thursday, saying there was nothing unusual about a slight delay in its availability.
"We see that across our own facilities also from time to time," Jorgensen added.